i was studying penicilin nd cephalosproins, im losing my mind thus was i need u yo do , need u to write the drugs acc to thier classification nd WHIH INFECTIONS ARE THEY USED FOR LIKE EHICH BACTERIAS, ND ARE THOSE G -VE OR +VE

Reading File

Finding Sources

Reading File

Loading Image

I now have everything I need for a complete, well-organized answer. Let me put it all together.

Penicillins & Cephalosporins - Complete Classification Guide

Mechanism of Action (Both Classes)

Both penicillins and cephalosporins are beta-lactam antibiotics. They are bactericidal - they kill bacteria by binding to Penicillin-Binding Proteins (PBPs) and blocking transpeptidase cross-linking of peptidoglycan chains in the bacterial cell wall.

Beta-lactam mechanism of action - inhibiting transpeptidase in bacterial cell wall synthesis

PART 1: PENICILLINS

Penicillins are divided into 4 groups based on their spectrum:

Group 1 - Natural Penicillins

Drug	Route
Penicillin G (benzylpenicillin)	IV/IM
Penicillin V (phenoxymethylpenicillin)	Oral

Spectrum: Narrow - G(+) and a few G(-) cocci

G(+): Streptococcus pyogenes, S. pneumoniae, Streptococcus viridans, Enterococcus (with aminoglycoside)
G(-): Neisseria meningitidis, Neisseria gonorrhoeae (if susceptible)
Others: Treponema pallidum (syphilis), anaerobes (except Bacteroides fragilis)

Used for:

Streptococcal pharyngitis/tonsillitis
Pneumococcal pneumonia (susceptible strains)
Meningococcal meningitis
Syphilis (Pen G is drug of choice)
Rheumatic fever prophylaxis
Enterococcal endocarditis (+ gentamicin)

Note: Does NOT cover beta-lactamase producing Staph aureus (MSSA or MRSA)

Group 2 - Penicillinase-Resistant (Anti-Staphylococcal) Penicillins

Drug	Route
Nafcillin	IV
Oxacillin	IV
Dicloxacillin	Oral
Flucloxacillin	Oral
(Methicillin - historical, no longer used)	-

Spectrum: Narrow - similar to natural penicillins BUT resistant to staphylococcal penicillinase

G(+): MSSA (Methicillin-Susceptible Staph aureus) - this is their specialty
Still active against Streptococci
Do NOT cover MRSA, G(-) rods, or Pseudomonas

Used for:

MSSA infections: skin/soft tissue (cellulitis, impetigo, folliculitis)
MSSA bacteremia and endocarditis
Osteomyelitis caused by MSSA

Group 3 - Aminopenicillins (Broad-Spectrum)

Drug	Route
Ampicillin	IV/IM/Oral
Amoxicillin	Oral
Amoxicillin + Clavulanate (Augmentin)	Oral
Ampicillin + Sulbactam (Unasyn)	IV

Spectrum: Broader than natural - adds G(-) coverage

G(+): Streptococci, Enterococcus faecalis
G(-): Haemophilus influenzae, E. coli, Proteus mirabilis, Salmonella, Shigella, some Klebsiella
Do NOT cover Pseudomonas
Hydrolyzed by many beta-lactamases (hence the combo with clavulanate/sulbactam)
Adding beta-lactamase inhibitor extends to: B. fragilis (anaerobe), beta-lactamase-producing H. influenzae, MSSA

Used for:

Otitis media (amoxicillin)
Sinusitis, community-acquired pneumonia
UTIs (E. coli)
Oral/dental infections (amoxicillin-clavulanate)
Cat, dog, human bites (amoxicillin-clavulanate = drug of choice)
Meningitis (IV ampicillin - Listeria, Group B Strep, E. coli in neonates)
Enterococcal endocarditis (IV ampicillin)
Typhoid/Salmonella (ampicillin)

Group 4 - Antipseudomonal (Extended-Spectrum) Penicillins

Drug	Combination
Piperacillin + Tazobactam (Pip-Tazo, Zosyn)	Always used with tazobactam
Ticarcillin + Clavulanate

Spectrum: The broadest penicillin spectrum

G(+): Streptococci, Enterococcus (variable)
G(-): Pseudomonas aeruginosa, Klebsiella, E. coli, Proteus, Enterobacter, H. influenzae
Anaerobes: B. fragilis (covered with tazobactam)
Do NOT cover MRSA

Used for:

Hospital-acquired/ventilator-associated pneumonia
Febrile neutropenia
Intra-abdominal infections
Complicated UTIs
Sepsis in immunocompromised patients

PART 2: CEPHALOSPORINS

Organized by generations - each higher generation shifts spectrum from G(+) toward G(-):

Key rule to remember: As generation number increases → more G(-) coverage, less G(+) coverage (with exception of 5th gen)

1st Generation - "Gram POSITIVE kings"

Drug	Route
Cefazolin	IV/IM
Cephalexin (Keflex)	Oral
Cefadroxil	Oral

Spectrum:

G(+) - Strong: MSSA, Streptococci (NOT MRSA, NOT Enterococcus)
G(-) - Limited: E. coli, Proteus mirabilis, Klebsiella pneumoniae (the "PEcK" organisms)
No anaerobes, no Pseudomonas

Used for:

Skin/soft tissue infections (MSSA, Streptococcal cellulitis)
Surgical prophylaxis (Cefazolin - most common surgical prophylaxis antibiotic)
Simple UTIs (E. coli, Klebsiella)
Streptococcal/MSSA bone and joint infections

2nd Generation - Adds H. influenzae & Moraxella + some anaerobes

Drug	Notes
Cefuroxime	G(-) respiratory coverage
Cefaclor	Oral
Cefprozil	Oral
Cefamandole
Cefoxitin	+ anaerobic coverage (B. fragilis)
Cefotetan	+ anaerobic coverage (B. fragilis)

Spectrum:

G(+): Streptococci, MSSA (weaker than 1st gen)
G(-): H. influenzae, Moraxella catarrhalis, E. coli, Klebsiella, Proteus
Anaerobes (cefoxitin/cefotetan only): B. fragilis
No Pseudomonas

Used for:

Community-acquired pneumonia (S. pneumoniae + H. influenzae + M. catarrhalis)
Acute otitis media, sinusitis
Surgical prophylaxis for abdominal/GYN surgery (cefoxitin/cefotetan)
Pelvic inflammatory disease (PID)
Mild intra-abdominal infections

3rd Generation - Broad G(-) coverage, less G(+)

Drug	Notes
Ceftriaxone	IV/IM - most commonly used; crosses BBB
Cefotaxime	IV - crosses BBB
Ceftazidime	IV - ONLY 3rd gen with Pseudomonas coverage
Cefdinir	Oral
Cefixime	Oral
Cefpodoxime	Oral
Cefoperazone	Also has some Pseudomonas activity

Spectrum:

G(+): S. pneumoniae (moderate), Streptococci - weaker than earlier gens; NO MSSA reliability
G(-) - Strong: Enterobacteriaceae (E. coli, Klebsiella, Enterobacter, Proteus, Serratia), H. influenzae, N. meningitidis, N. gonorrhoeae
Ceftazidime only: Pseudomonas aeruginosa (but LOSES most G(+) activity)
No MRSA, no Enterococcus

Used for:

Ceftriaxone is a workhorse:
- Bacterial meningitis (H. influenzae, N. meningitidis, susceptible S. pneumoniae)
- Community-acquired pneumonia (severe)
- Late-stage Lyme disease
- Gonorrhea (drug of choice now - IM ceftriaxone)
- Streptococcal endocarditis
- Typhoid/Salmonella
Ceftazidime:
- Pseudomonal pulmonary infections (cystic fibrosis)
- Post-neurosurgical meningitis
- Febrile neutropenia

4th Generation - Broad spectrum both G(+) and G(-)

Drug	Notes
Cefepime	IV - broad G(+) and G(-) including Pseudomonas
Cefpirome	IV

Spectrum:

G(+): Similar to ceftriaxone (Streptococci, MSSA) - better than 3rd gen
G(-): Pseudomonas aeruginosa, Enterobacteriaceae, AmpC beta-lactamase-producing organisms (Enterobacter)
No MRSA, no Enterococcus

Used for:

Febrile neutropenia
Hospital-acquired pneumonia
Bacteremia
Complicated UTIs
Intra-abdominal infections

5th Generation - MRSA coverage (unique!)

Drug	Notes
Ceftaroline (Teflaro)	IV - only beta-lactam that covers MRSA
Ceftobiprole	IV

Spectrum:

G(+) - Special: MRSA (unique - no other cephalosporin does this), MSSA, Streptococci
G(-): Similar to 3rd gen Enterobacteriaceae - but NO Pseudomonas
No Pseudomonas, no Enterococcus

Used for:

Community-acquired pneumonia
Skin and soft tissue infections (including MRSA)
Emerging use: bacteremia

Quick Memory Summary Table

Class	Key Drugs	Main G(+)	Main G(-)	Special
Natural Pen	Pen G, Pen V	Strep, Pneumococcus	N. meningitidis	Syphilis (T. pallidum)
Anti-Staph Pen	Nafcillin, Dicloxacillin	MSSA	None	Pen-resistant Staph
Aminopenicillins	Ampicillin, Amoxicillin (+BLI)	Strep, Enterococcus	H. flu, E. coli, Salmonella	Dog bites (Augmentin)
Anti-Pseudomonal	Pip-Tazo	Strep	Pseudomonas, Enterobacters	Febrile neutropenia
Ceph 1st	Cefazolin, Cephalexin	MSSA, Strep	PEcK (limited)	Surgical prophylaxis
Ceph 2nd	Cefuroxime, Cefoxitin	Strep, MSSA	H. flu, Moraxella	Cefoxitin: B. fragilis
Ceph 3rd	Ceftriaxone, Ceftazidime	S. pneumoniae (weak)	Enterobacteriaceae, N. gonorrhoeae	Ceftazidime = Pseudomonas
Ceph 4th	Cefepime	MSSA, Strep	Pseudomonas, AmpC	Broad both sides
Ceph 5th	Ceftaroline	MRSA	Enterobacteriaceae	Only beta-lactam vs MRSA

The Big "Gaps" - What These Drugs NEVER Cover

MRSA - only ceftaroline (5th gen) covers it; all other penicillins/cephalosporins fail
Enterococcus faecium (VRE) - not covered by cephalosporins; aminopenicillins cover faecalis
Atypicals (Mycoplasma, Chlamydia, Legionella) - no beta-lactam covers these
Listeria - cephalosporins don't work; use ampicillin

Sources: Harrison's Principles of Internal Medicine 22E, Dermatology 2-Volume Set 5e, Sherris & Ryan's Medical Microbiology 8th Ed, Goodman & Gilman's Pharmacological Basis of Therapeutics

THANKS now can u help me withother beta lactam drugs- azertreonam, imipenem, droeipenem, meropenem, ertapenem, and other cell wall or membrane active agents - vancomycin, fosfomycin, daptomycin, bacitracin, cycloserine please use katzung

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

I have all the information needed. Let me now compile the full organized response directly from Katzung.

Other Beta-Lactams + Cell Wall/Membrane-Active Agents

(Katzung's Basic and Clinical Pharmacology, 16th Edition)

PART 1: OTHER BETA-LACTAM DRUGS

A. MONOBACTAMS - Aztreonam

Feature	Detail
Mechanism	Binds transpeptidases - inhibits cell wall synthesis (same as other beta-lactams)
Ring structure	Monocyclic beta-lactam ring (mono = one ring, unlike penicillins/cephalosporins which are bicyclic)
Spectrum	G(-) ONLY - no G(+), no anaerobes

Bacteria covered (G- only):

Pseudomonas aeruginosa
Enterobacteriaceae (E. coli, Klebsiella, Proteus, Serratia, Enterobacter)
H. influenzae, N. gonorrhoeae, N. meningitidis
Similar gram-negative spectrum to 3rd-gen cephalosporins

Bacteria NOT covered:

All G(+) organisms (zero activity)
All anaerobes
Resistant to many beta-lactamases EXCEPT AmpC and ESBLs

Clinical uses:

Serious G(-) infections: pneumonia, meningitis, sepsis
Key advantage: safe in patients with penicillin allergy (no cross-reactivity with penicillins)
Caution: potential cross-reactivity with ceftazidime (structurally similar) - avoid if severe ceftazidime allergy

Route/Dosing: IV, 1-2g every 8 hours (half-life 1-2 hours, prolonged in renal failure)

B. CARBAPENEMS

All carbapenems are beta-lactams with the widest spectrum of all - they resist most beta-lactamases.

Shared mechanism: Bind penicillin-binding proteins (PBPs), inhibit transpeptidation - bactericidal

What carbapenems cover (shared):

G(+): Streptococci, MSSA, many pneumococci (including pen-non-susceptible strains)
G(-): Almost all Enterobacteriaceae (E. coli, Klebsiella, Proteus, Enterobacter, Serratia), H. influenzae
Anaerobes: Bacteroides fragilis and most others
Highly active vs ESBL-producing organisms and Enterobacter (resistant to their beta-lactamase)

What NO carbapenem covers:

MRSA
Enterococcus faecium (VRE)
Clostridioides difficile
Burkholderia cepacia, Stenotrophomonas maltophilia
Carbapenem-resistant Enterobacterales (CRE - carbapenemase producers)

1. Imipenem-Cilastatin

Feature	Detail
Extra coverage	Pseudomonas aeruginosa, Acinetobacter
Special note	Inactivated by renal dehydropeptidases - must be combined with cilastatin (a renal dehydropeptidase inhibitor) to prevent renal degradation
CSF penetration	Yes - can treat meningitis
Route/Dose	IV, 0.25-0.5g every 6-8 hours
Half-life	1 hour
Key toxicity	Seizures (most common among carbapenems - especially in renal failure when drug accumulates)
Cross-allergy	<1% cross-reactivity with penicillin allergy

2. Meropenem (+ Meropenem-Vaborbactam)

Feature	Detail
Coverage	Same broad spectrum as imipenem; slightly more active vs G(-), slightly less active vs G(+)
Pseudomonas	Yes - covered
Acinetobacter	Yes - covered
Special note	NOT degraded by renal dehydropeptidase - no cilastatin needed
CSF penetration	Yes
Route/Dose	IV, 0.5-1g every 8 hours
Seizure risk	Much lower than imipenem
Meropenem-Vaborbactam	Vaborbactam is a beta-lactamase inhibitor added to restore activity against KPC-producing CRE (carbapenemase producers)

3. Ertapenem

Feature	Detail
Key difference	Does NOT cover Pseudomonas aeruginosa or Acinetobacter - use other carbapenems for these!
Coverage	G(+), G(-) Enterobacteriaceae, anaerobes - same as others minus Pseudomonas/Acinetobacter
Special note	NOT degraded by renal dehydropeptidase - no cilastatin needed
CSF penetration	No - limited CNS penetration
Half-life	Longer - allows once-daily dosing
Uses	Community-acquired infections, ESBL infections, intra-abdominal, complicated UTI, pelvic infections - where Pseudomonas is NOT a concern

4. Doripenem

Similar to imipenem and meropenem in spectrum (broad, including Pseudomonas)
Slightly greater G(-) activity, slightly less G(+) than imipenem
NOT degraded by renal dehydropeptidase
No longer available in the USA (withdrawn from market)

Carbapenem Comparison at a Glance

Drug	Pseudomonas	Acinetobacter	Needs Cilastatin	CSF	Seizure Risk
Imipenem	✅	✅	YES	✅	High
Meropenem	✅	✅	No	✅	Low
Ertapenem	❌	❌	No	❌	Low
Doripenem	✅	✅	No	✅	Low

PART 2: CELL WALL & MEMBRANE-ACTIVE AGENTS

C. VANCOMYCIN (Glycopeptide)

Mechanism: Binds the D-Ala-D-Ala terminus of nascent peptidoglycan - blocks transglycosylase, preventing peptidoglycan elongation and cross-linking. Also damages the cell membrane. Bactericidal for G(+).

Why only G(+)? Vancomycin is a large molecule - it cannot penetrate the outer membrane of gram-negative bacteria.

Spectrum - G(+) only:

MRSA (methicillin-resistant S. aureus) - this is its main indication
MSSA, S. epidermidis
Streptococcus pneumoniae (including pen-resistant strains)
Enterococcus faecalis and faecium (but note VRE resistance)
Clostridioides difficile (oral only, for CDI colitis)
Most gram-positive anaerobes

Resistance (VRE): Enterococci modify D-Ala-D-Ala to D-Ala-D-Lac - vancomycin can no longer bind.

Clinical uses:

MRSA infections (bacteremia, endocarditis, pneumonia, osteomyelitis, meningitis)
Serious G(+) infections in penicillin-allergic patients
C. difficile colitis (oral route - since it's not absorbed, stays in gut)
Surgical prophylaxis when MRSA is a concern

Pharmacokinetics:

Poorly absorbed orally - IV for systemic, oral only for gut infections (CDI)
CSF penetration 7-30% with meningeal inflammation
Renally cleared - dose adjust in renal failure
Monitoring: AUC/MIC ratio ≥400 preferred (or traditional trough monitoring)

Toxicities:

Nephrotoxicity (especially with aminoglycosides)
"Red Man Syndrome" - flushing, erythema, hypotension from histamine release during rapid infusion (slow infusion prevents this - not a true allergy)
Ototoxicity (rare)

D. DAPTOMYCIN (Lipopeptide)

Mechanism: Cyclic lipopeptide from Streptomyces roseosporus. Binds the bacterial cell membrane via calcium-dependent insertion of its lipid tail → depolarizes the membrane → potassium efflux → rapid cell death. Distinct mechanism from all cell-wall agents.

Spectrum - G(+) only:

MRSA (including MRSA strains with reduced vancomycin susceptibility - VISA/VRSA)
VRE (Enterococcus faecalis and faecium)
Streptococcus spp., Staphylococcus spp.
More rapid bactericidal activity than vancomycin

Clinical uses:

Skin and soft tissue infections: 4 mg/kg IV once daily
S. aureus bacteremia and right-sided endocarditis: 6 mg/kg IV once daily
VRE infections

KEY CONTRAINDICATION: Do NOT use for pneumonia - daptomycin is inactivated by pulmonary surfactant. Use something else for lung infections!

Pharmacokinetics:

IV only - renally cleared
Dose adjust in renal insufficiency (CrCl <30 mL/min)

Toxicity: Myopathy/rhabdomyolysis - monitor CPK weekly. Hold statins during daptomycin therapy.

E. FOSFOMYCIN

Mechanism: Analog of phosphoenolpyruvate. Inhibits enolpyruvate transferase by binding its cysteine active site - blocks the first step in peptidoglycan synthesis (formation of UDP-N-acetylmuramic acid precursor). Earliest-acting cell wall agent.

Spectrum: Both G(+) and G(-) (at high concentrations ≥125 mcg/mL)

E. coli, Klebsiella pneumoniae, Enterococcus faecalis
Achieves high urinary concentrations - ideal for UTIs

Clinical uses:

Single 3g oral dose for uncomplicated lower UTI in women (its primary indication)
Limited data supports multi-dose regimens for male UTI/prostatitis
Safe in pregnancy
Synergistic with beta-lactams, aminoglycosides, fluoroquinolones

Pharmacokinetics:

Oral (only form approved in USA) and IV (available elsewhere)
Oral bioavailability ~40%, excreted unchanged in urine
Half-life ~4 hours

Resistance: Inadequate drug transport into the cell.

F. BACITRACIN

Mechanism: Cyclic peptide mixture (from Bacillus subtilis). Interferes with dephosphorylation of the lipid carrier that transports peptidoglycan subunits to the growing cell wall - essentially traps the lipid carrier and stops cell wall building.

Spectrum: G(+) only

Active against Staphylococci, Streptococci, and other gram-positive organisms
No cross-resistance with other antibiotics

Route: TOPICAL ONLY

Highly nephrotoxic if given systemically - never given IV/IM
Poorly absorbed from skin - stays local

Clinical uses:

Topical skin/wound infections with mixed G(+) flora
Available as ointment 500 units/g, often combined with polymyxin or neomycin (e.g., Neosporin)
Do NOT use prophylactically on wounds - commonly causes hypersensitivity reactions

G. CYCLOSERINE

Mechanism: Structural analog of D-alanine. Inhibits two enzymes:

Alanine racemase - converts L-alanine to D-alanine
D-alanyl-D-alanine ligase - joins two D-alanines

Result: D-alanine cannot be incorporated into the peptidoglycan pentapeptide - cell wall synthesis fails.

Spectrum: Active against many G(+) and G(-) organisms, BUT used almost exclusively for:

Tuberculosis (TB) - specifically MDR-TB (multi-drug resistant TB) caused by Mycobacterium tuberculosis resistant to first-line agents
Second-line TB drug

Clinical use:

MDR-TB treatment
Dose: 0.5-1g/day in 2-3 divided doses
Blood levels reach 20-30 mcg/mL after 0.25g dose - sufficient to inhibit mycobacteria

Pharmacokinetics:

Oral, well absorbed
Widely distributed in tissues including CSF
Mostly excreted unchanged in urine

Toxicities - CNS (dose-related, serious):

Headaches, tremors
Acute psychosis
Convulsions/seizures
Keep dose below 0.75g/day to minimize CNS effects

Master Summary Table

Drug	Class	G(+)	G(-)	Pseudomonas	Anaerobes	Key Use	Key Toxicity
Aztreonam	Monobactam	❌	✅	✅	❌	G(-) infections in pen-allergic pts	Minimal; cross-react w/ ceftazidime
Imipenem	Carbapenem	✅	✅	✅	✅	Serious mixed/resistant infections	Seizures, needs cilastatin
Meropenem	Carbapenem	✅	✅	✅	✅	Serious infections, meningitis	Low seizure risk
Ertapenem	Carbapenem	✅	✅	❌	✅	Community ESBL infections	No Pseudo coverage!
Doripenem	Carbapenem	✅	✅	✅	✅	Off market in USA	-
Vancomycin	Glycopeptide	✅ MRSA/VRE	❌	❌	G(+) only	MRSA, CDI (oral)	Nephro, Red Man Syndrome
Daptomycin	Lipopeptide	✅ MRSA/VRE	❌	❌	❌	MRSA bacteremia, VRE	Myopathy; NOT for pneumonia
Fosfomycin	Phosphonate	✅	✅	❌	❌	Uncomplicated UTI (single dose)	Minimal
Bacitracin	Cyclic peptide	✅	❌	❌	❌	Topical skin only	Nephrotoxic if systemic
Cycloserine	D-Ala analog	✅	✅	❌	❌	MDR-TB only	Seizures, psychosis

Source: Katzung's Basic and Clinical Pharmacology, 16th Edition

Two exam pearls to tattoo in your brain:

Aztreonam = G(-) only beta-lactam - safe in penicillin allergy, structural similarity to ceftazidime is the only concern
Ertapenem = carbapenem with no Pseudomonas coverage - the one exception in its class

This is a shared conversation. Sign in to Orris to start your own chat.